Ceralifimod

Drug Profile

Ceralifimod

Alternative Names: MSC-2430913A; ONO-4641; S1P agonist - Ono Pharmaceutical

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Class Azetidines; Carboxylic acids; Naphthalenes; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 27 Dec 2014 Ono terminates a phase III trial in Multiple Sclerosis in Austria, Belgium, Estonia, Germany, Greece, Hungary, Latvia, Portugal and Spain (EudraCT2013-002351-15; EudraCT2013-003126-83)
  • 19 Jun 2014 Merck terminates its licence for ceralifimod
  • 16 Apr 2014 Phase-III clinical trials in Multiple sclerosis in Belgium (PO) (EudraCT2013-003126-83)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top